Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
173
-
Total 13F shares, excl. options
-
145M
-
Shares change
-
-793K
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
-$14.6M
-
Put/Call ratio
-
0.41
-
Number of buys
-
76
-
Number of sells
-
-89
-
Price
-
$7.62
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q4 2022
209 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q4 2022.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 173 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 145M shares
of 194M outstanding shares and own 74.57% of the company stock.
Largest 10 shareholders include Kohlberg Kravis Roberts & Co. L.P. (31.1M shares), VIKING GLOBAL INVESTORS LP (26.6M shares), VANGUARD GROUP INC (10.6M shares), BlackRock Inc. (9.77M shares), STATE STREET CORP (8.84M shares), Aisling Capital Management LP (6.07M shares), HHLR ADVISORS, LTD. (5.19M shares), AMERICAN INTERNATIONAL GROUP, INC. (3.72M shares), CITADEL ADVISORS LLC (2.88M shares), and D. E. Shaw & Co., Inc. (2.7M shares).
This table shows the top 173 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.